Here, we aimed to: (1) estimate the probability of SVR after DAA treatment initiation between 2014 and 2020, overall and by subgroups defined by sex, age, cirrhosis, mode of HIV acquisition, CD4 cell count and calendar year of DAA initiation using a large international consortium of cohorts of individuals with HIV and HCV co‐infection and (2) compare these proportions with those obtained using the parametric g‐formula to impute SVR status for individuals with no SVR assessment. The gene discussed is CD4; the disease is Cirrhosis.